Key Takeaways

GHRP-2 is a real pharmacologic secretagogue, not an invented wellness label. It can stimulate the pituitary GH axis, and Japan uses a specific IV pralmorelin product for diagnosis.
The evidence does not support treating chronic clinic injections or nasal sprays as the same intervention, and it does not prove fat loss, muscle gain, injury recovery, better sleep, or anti-aging.
Human appetite studies are especially important because they reported increased food intake—the opposite of the simple "fat-loss peptide" story.

‍

[PMDA, 2025; Laferrère et al., 2005; Laferrère et al., 2006]

‍

GHRP-2: an unapproved U.S. synthetic peptidic growth hormone secretagogue—also called pralmorelin—with the sequence D-Ala-3-(2-naphthyl)-D-Ala-Ala-Trp-D-Phe-Lys-NH₂; it is a ghrelin-receptor agonist used as a single-dose intravenous diagnostic agent in Japan, but chronic subcutaneous, nasal, oral, or stacked wellness use remains investigational.

Overview

GHRP-2 has a stronger human scientific record than many peptides circulating in wellness markets, but the legitimacy is narrow. Same-molecule studies show that pralmorelin can acutely stimulate growth hormone secretion, and Japan regulates a pralmorelin hydrochloride product as a supervised, fasting, single-dose intravenous growth hormone stimulation test. That evidence supports endocrine pharmacology and a diagnostic use. It does not establish chronic subcutaneous or intranasal treatment for fat loss, muscle gain, recovery, sleep, or anti-aging in U.S. patients. [PMDA, 2025; Pihoker et al., 1998; Arvat et al., 1997]

The central compliance problem is therefore route-and-purpose transfer. A 100-µg IV diagnostic challenge administered once under controlled conditions is not the same product experiment as repeated outpatient injections, nasal sprays, oral formulations, or blends with CJC-1295, modified GRF 1-29, or sermorelin. Nor is Japanese approval equivalent to FDA approval. In the United States, GHRP-2 is not FDA-approved; FDA's current 503A nomination table places GHRP-2 in Category 3, while the 503B table separates non-injectable/non-nasal GHRP-2 in Category 1 from injectable and nasal GHRP-2 in Category 2 because of significant safety concerns. [FDA, 2026; FDA, 2025; PMDA, 2025]

FDA's risk discussion is specific enough to govern tone. For injectable and nasal GHRP-2, the agency cites potential immunogenicity from aggregation and peptide-related impurities, added API-characterization complexity from an unnatural amino acid, and reports of increased insulin requirements, death in critically ill study subjects, infection, and pancreatitis, while noting that causality has not been established. These are not proof that GHRP-2 caused every event, but they are incompatible with "safe natural GH booster" or "low-risk alternative to HGH" copy. [FDA, 2026]

The outcome evidence is also more complicated than clinic shorthand suggests. Human studies support acute GH release and, in some settings, higher IGF-1 during sustained exposure. Yet controlled human appetite studies found that GHRP-2 increased food intake in healthy and obese men. Small pediatric programs produced mixed growth outcomes, including later intranasal work in which higher endogenous GH secretion did not translate into increased growth. Biomarker movement is real; broad body-composition and anti-aging outcomes remain unproven. [Bowers et al., 2004; Laferrère et al., 2005; Laferrère et al., 2006; Tanaka et al., 2014]

What it is

GHRP-2 stands for growth hormone-releasing peptide-2. Its international nonproprietary name is pralmorelin. NCATS lists the free-base sequence as D-Ala-3-(2-naphthyl)-D-Ala-Ala-Trp-D-Phe-Lys-NH₂, with a molecular formula of C₄₅H₅₅N₉O₆, molecular weight of 817.9766 Da. The molecule is synthetic and includes non-natural stereochemistry and a 2-naphthylalanine residue; it is not endogenous ghrelin. [NCATS Inxight Drugs, 2025]

The Japanese product is a distinct salt and dosage form. The current package insert identifies pralmorelin hydrochloride in a lyophilized 100-µg vial with 25 mg D-mannitol, reconstituted in 10 mL saline for a single slow IV diagnostic administration. That regulated vial, its route, and its diagnostic procedure cannot be collapsed into a generic "GHRP-2" powder sold for repeated subcutaneous use. [PMDA, 2025]

A second identity problem is "acetate" language. Consumer and research-vendor pages often use free-base, acetate, or generic vial labels without documenting whether the counterion, hydration state, peptide-content correction, impurity profile, or intact sequence matches the Japanese product. Counterion language is not cosmetic: it can affect assay calculations, solubility, stability, reconstitution, and the amount of active peptide present. No current U.S. approved GHRP-2 label bridges these forms. [FDA, 2026; PMDA, 2025]

Material	What it is	Why it cannot be collapsed into "GHRP-2"
Endogenous ghrelin	A stomach-derived acylated hormone and the endogenous GHSR1a ligand.	Shared receptor biology does not make ghrelin and pralmorelin the same molecule, exposure pattern, or clinical product. [Kojima et al., 1999]
GHRP-2 / pralmorelin free base	Synthetic hexapeptide active moiety; MW 817.9766.	This is the general target molecule, but route, salt, purity, and formulation still matter. [NCATS Inxight Drugs, 2025]
Pralmorelin hydrochloride/dihydrochloride	Japanese diagnostic drug substance in GHRP KAKEN100 Injection.	This regulated salt/product has a defined single-dose IV diagnostic use; it is not a chronic SC product. [PMDA, 2025]
Somatropin / recombinant hGH	Exogenous recombinant human growth hormone.	Direct hormone replacement has different PK, dose control, indications, warnings, and clinical evidence.
GHRH / sermorelin / CJC-1295 / modified GRF 1-29	GHRH-receptor agonists or analogues acting at a different receptor.	GHRH-receptor and ghrelin-receptor stimulation can interact, but one class does not inherit the other's evidence.
GHRP-6, hexarelin, ipamorelin, macimorelin, ibutamoren	Other peptidic or nonpeptidic growth hormone secretagogues.	Shared class or receptor does not establish equal potency, selectivity, appetite effects, route behavior, or safety.

How it's proposed to work

The most defensible mechanistic anchor is agonism at the growth hormone secretagogue receptor type 1a, or GHSR1a. The receptor was cloned from pituitary and hypothalamic tissue before ghrelin itself was discovered, and later work established ghrelin as the endogenous ligand. GHRP-2 is a synthetic agonist at this receptor rather than a GHRH-receptor agonist. [Howard et al., 1996; McKee et al., 1997; Kojima et al., 1999]

At the receptor level, GHSR1a is generally coupled to Gq/11 signaling, with phospholipase C activation, inositol-trisphosphate generation, intracellular calcium mobilization, and GH release from pituitary somatotrophs. Human endocrine studies make the downstream GH response clinically observable, while Japanese labeling describes effects at both hypothalamic and pituitary levels. [Arvat et al., 1997; PMDA, 2025]

The GH response is not independent of the rest of the neuroendocrine axis. GHRP-2 and endogenous GHRH can act synergistically or interdependently, while somatostatin tone constrains secretion. That physiology explains why commercial blends pair a GHSR agonist with a GHRH analogue. GHRP-2 is also not fully "GH-selective" in the way market pages sometimes imply. In healthy adults, Arvat and colleagues reported increases not only in GH but also in prolactin, ACTH, and cortisol. Separately, human feeding studies found increased food intake, consistent with ghrelin-receptor biology. [Gondo et al., 2001; Van den Berghe et al., 1999; Arvat et al., 1997; Laferrère et al., 2005; Laferrère et al., 2006]

Sustained exposure can raise IGF-1 and related binding proteins, as shown in a 30-day continuous subcutaneous infusion study in older adults. But a higher GH or IGF-1 biomarker is not equivalent to improved strength, reduced fat mass, better recovery, or longer healthspan. [Bowers et al., 2004]

Common forms in circulation

The clearest regulated form is Japan's GHRP KAKEN100 Injection: a 100-µg lyophilized vial of pralmorelin hydrochloride with D-mannitol, reconstituted in 10 mL saline and administered once by slow IV injection in the fasting, resting patient for diagnosis of growth hormone deficiency. These are label facts about a diagnostic procedure, not dosing guidance for treatment. [PMDA, 2025]

In U.S. compounding materials, route is decisive. FDA's May 2026 503A nomination table places GHRP-2 in Category 3, meaning it was nominated without adequate support. FDA's March 2025 503B table places GHRP-2 excluding injectable and nasal routes in Category 1, while injectable and nasal GHRP-2 remain in Category 2 because FDA identified significant safety concerns. [FDA, 2026; FDA, 2025]

Consumer circulation is broader and less standardized: standalone lyophilized vials discussed for subcutaneous injection, intranasal sprays, legacy oral formulations, and blends pairing GHRP-2 with CJC-1295, modified GRF 1-29, sermorelin, GHRP-6, or other secretagogues. Those pages document market behavior; they do not validate route, dose, sterility, stability, or efficacy. [Weiss Wellness + Beauty, n.d.; Kane Orthopedic Institute, n.d.]

Names and aliases

Scientific and regulatory aliases include GHRP-2, GHRP 2, growth hormone-releasing peptide-2, pralmorelin, KP-102, KP-102-D, KP-102-LN, and GPA-748. Japanese materials use pralmorelin hydrochloride and the brand GHRP KAKEN100 Injection. [NCATS Inxight Drugs, 2025; PMDA, 2025]

Common pairing language includes GHRP-2 + CJC-1295, GHRP-2 + modified GRF 1-29, sermorelin + GHRP-2, and three-peptide blends that add GHRP-6. These pairings are marketed as complementary hypothalamic/pituitary signaling or "synergy." They should be treated as commercial protocol logic unless the exact combination, formulation, route, and outcome have been tested in a controlled human study. [Core Peptides, 2024; Biotech Peptides, 2026]

Regulatory status

GHRP-2 is not FDA-approved for any indication in the United States. FDA states more generally that compounded drugs are not FDA-approved and do not undergo the agency's premarket review for safety, effectiveness, and quality. [FDA, 2026]

For 503A traditional compounding, the current May 14, 2026 nomination table lists GHRP-2 in Category 3: bulk drug substances nominated without adequate support. [FDA, 2026]

For 503B outsourcing facilities, the March 21, 2025 table separates route categories. GHRP-2 excluding injectable and nasal routes appears in Category 1, meaning it was under evaluation under the applicable interim policy. Injectable and nasal GHRP-2 appear in Category 2, the significant-safety-risk category. This split is important because wellness use is commonly injectable or nasal—the routes for which FDA's concern is most explicit. [FDA, 2025]

Japan provides a different regulatory example. Pralmorelin hydrochloride was approved there in 2004 and launched in 2005 as a prescription diagnostic drug for growth hormone deficiency. The current label specifies a single fasting IV challenge and timed GH sampling; it does not authorize chronic anti-aging, body-composition, recovery, or bodybuilding treatment. Japan's postmarketing re-examination found no adverse reactions in a 503-case special-use survey, while preapproval domestic trials reported adverse reactions in 86 of 227 patients, most commonly abdominal sounds, warmth, sweating, and leukocytosis. Those data belong to a one-time diagnostic setting and should not be used to characterize repeated outpatient use as safe. [PMDA, 2014; PMDA, 2025]

GHRP-2 is not listed on the FDA's July 23–24, 2026 Pharmacy Compounding Advisory Committee agenda. That meeting addresses BPC-157, KPV, TB-500, MOTS-C, emideltide/DSIP, Semax, and Epitalon. GHRP-2 should not be described as "up for approval," "being greenlit," or covered by any favorable or unfavorable vote from that meeting. [FDA, 2026; Federal Register, 2026]

Safety

Human safety information exists, but it is fragmented by route, duration, and purpose. The Japanese label reports acute adverse reactions including warmth, hypotension, abdominal sounds, nausea and other gastrointestinal symptoms, somnolence, dizziness, rhinorrhea, sweating, thirst, hunger, fatigue, flushing, and headache. Pregnancy is contraindicated. The product's healthy-adult half-life is reported at approximately 0.42–0.69 hours, and protein binding at approximately 83.1%–86%. These data describe a regulated diagnostic exposure, not repeated clinic use. [PMDA, 2025]

Broader endocrine monitoring is biologically justified. GHRP-2 can increase GH, IGF-1, prolactin, ACTH, and cortisol; human studies also document appetite and food-intake effects. FDA reports increased insulin requirement in some recipients and includes infection, pancreatitis, and death in critically ill study subjects among serious reported events, with causality unresolved. Chronic or combination programs therefore cannot be described as low-monitoring or inherently safer than recombinant GH. [Arvat et al., 1997; Bowers et al., 2004; Laferrère et al., 2005; FDA, 2026]

Purported benefits, by evidence

Purported benefit	What the evidence supports	What it does not support	Source
Acute GH release / "GH optimization"	IV, SC, intranasal, oral, and infusion studies show that GHRP-2 can stimulate endogenous GH under specified conditions.	Does not support generalized "hormone optimization," symptom benefit, or chronic outpatient efficacy.	[Arvat et al., 1997; Pihoker et al., 1998; Bowers et al., 2004]
Diagnosis of growth hormone deficiency	A defined pralmorelin hydrochloride IV challenge is used with timed GH sampling to support diagnosis.	Does not support U.S. FDA approval, chronic treatment, anti-aging, or a home-use stimulation test.	[PMDA, 2025; PMDA, 2014]
Pediatric growth velocity	Older pediatric work explored intranasal or graded long-term administration, with some growth-related signals.	Does not support an established growth treatment; later intranasal work found higher endogenous GH did not promote growth.	[Pihoker et al., 1997; Mericq et al., 1998; Tanaka et al., 2014]
Appetite / caloric intake	Single-dose studies in healthy and obese men reported increased food intake; pediatric oral work also tracked appetite/body weight.	Does not support "appetite-neutral," "minimal appetite effect," or a simple fat-loss positioning.	[Laferrère et al., 2005; Laferrère et al., 2006; Mericq et al., 2003]
Fat loss / body composition	GH/IGF-axis activation creates mechanistic interest, but the reviewed same-molecule human studies do not establish a modern chronic GHRP-2 fat-loss program.	"Fat-loss peptide," "visceral fat reducer," "body-recomposition therapy," or "melts fat." Appetite findings complicate the claim.	[Bowers et al., 2004; Laferrère et al., 2005]
Muscle gain / strength	Higher GH/IGF-1 can sound anabolic, and sustained infusion raised endocrine biomarkers.	Does not prove increased lean mass, strength, hypertrophy, or athletic performance from clinic GHRP-2.	[Bowers et al., 2004]
Critical-illness metabolic support	GHRP-2/TRH infusion was studied in protracted critical illness and affected pituitary hormone release and metabolic markers.	Does not support outpatient wellness use; critically ill populations, combination treatment, infusion, and serious safety context are non-equivalent.	[Van den Berghe et al., 1999; FDA, 2026]
"Natural" or safer than HGH	GHRP-2 stimulates endogenous GH rather than supplying recombinant GH directly.	Does not establish lower overall risk, physiologic dosing, fewer adverse effects, or freedom from glucose, cortisol, appetite, or immunogenicity concerns.	[Arvat et al., 1997; FDA, 2026]

Key literature

Arvat E, Di Vito L, Maccagno B, et al. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Peptides. 1997;18(6):885-891. Acute GH stimulation and non-GH endocrine effects involving prolactin, ACTH, and cortisol.

Laferrère B, Abraham C, Russell CD, Bowers CY. Growth hormone-releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab. 2005;90(2):611-614. Same-molecule evidence that GHRP-2 increased food intake in healthy men.

Laferrère B, Hart AB, Bowers CY. Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake. Obesity (Silver Spring). 2006;14(6):1056-1063. Food-intake stimulation in obese participants.

Bowers CY, Granda-Ayala R, Mohan S, Kuipers J, Baylink D, Veldhuis JD. Sustained elevation of pulsatile growth hormone secretion and insulin-like growth factor I, IGF-binding protein-3, and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women. J Clin Endocrinol Metab. 2004;89(5):2290-2300. Sustained biomarker effects during continuous SC infusion in older adults.

Tanaka T, et al. Increased secretion of endogenous GH after treatment with an intranasal GH-releasing peptide-2 spray does not promote growth in short children. Clin Pediatr Endocrinol. 2014;23(4):107-114. A direct guardrail: higher endogenous GH did not translate into increased growth in the studied children.

References

U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. Updated May 14, 2026.
U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Growth hormone releasing peptide-2 entry; content current 2026.
U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act. Updated March 21, 2025.
Pharmaceuticals and Medical Devices Agency. GHRP KAKEN100 Injection, current package insert; revised July 2025.
Pharmaceuticals and Medical Devices Agency. Re-examination report for GHRP KAKEN100 Injection (pralmorelin hydrochloride). February 5, 2014.
National Center for Advancing Translational Sciences. Inxight Drugs: Pralmorelin. Record edited March 31, 2025.
World Anti-Doping Agency. The 2026 Prohibited List. Effective January 1, 2026.
The Guardian. What are peptides, are they safe and is there evidence to back up the hype? April 4, 2026.
The New Yorker. Why Are People Injecting Themselves with Peptides? April 2026.

GHRP-2 (Pralmorelin)